Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.
复制标题
DOI：
10.1007/s10549-011-1906-3
复制
发表时间：
2012-02
影响因子：
3.8
通讯作者：
Vahdat LT
中科院分区：
文献类型：
--
作者：
Jain S;Ward MM;O'Loughlin J;Boeck M;Wiener N;Chuang E;Cigler T;Moore A;Donovan D;Lam C;Cobham MV;Schneider S;Christos P;Baergen RN;Swistel A;Lane ME;Mittal V;Rafii S;Vahdat LT
动物模型已经证明了骨髓来源的VEGFR1+造血祖细胞（HPCs）和VEGFR2+内皮祖细胞（EPCs）在转移进展中的关键作用。我们探索这些细胞是否可以预测乳腺癌（BC）患者的复发和反应。2项研究纳入了132例1至4期BC患者。采用流式细胞术检测外周血单个核细胞循环CD45+/CD34+/VEGFR1+ HPCs和CD45dim/CD133+/VEGFR2+ EPCs。根据RECIST的反应，分析1)无明显疾病复发患者和2)转移患者HPCs和EPCs的变化。在研究开始时，102名患者没有疾病证据，30名患者有转移性BC。7例在检查、实验室和影像学检查中未发现BC的患者在研究期间出现复发。中位HPC/mL（范围）从645.8（23.5-1914）增加，p=0.016，其次是临床复发前中位EPC/mL从21.3（4.7-42.5）增加到94.7 (28.2-201.3),p=0.016。在进展性转移患者中，进展前的中位HPC/mL从1696（10-16470）增加到5124 (374-77605),p=0.0009，中位EPC/mL从26（0-560）增加到71 (0-615),p=0.10。在反应性疾病患者中，中位HPC/mL从6147（912-85070）降至633 (47-18065),p=0.05， EPC/mL从46（0-197）降至23 (0-105),p=0.41。在病情稳定的患者中，这些细胞随着时间的推移没有显著变化。循环骨髓来源的造血干细胞和内皮祖细胞预测BC患者的复发和疾病进展。
Animal models have demonstrated the critical role of bone marrow-derived VEGFR1+ hematopoietic progenitor cells (HPCs) and VEGFR2+ endothelial progenitor cells (EPCs) in metastatic progression. We explored whether these cells could predict relapse and response in breast cancer (BC) patients. 132 patients with stages 1 to 4 BC were enrolled on 2 studies. Circulating CD45+/CD34+/VEGFR1+ HPCs and CD45dim/CD133+/VEGFR2+ EPCs were assessed from peripheral blood mononuclear cells using flow cytometry. Changes in HPCs and EPCs were analyzed in 1) patients without overt disease that relapsed and 2) metastatic patients according to response by RECIST. At study entry, 102 patients were without evidence of disease and 30 patients had metastatic BC. Seven patients without evidence of BC by exam, labs, and imaging developed recurrence while on study. Median HPC/mL (range) increased from 645.8 (23.5-1914), p=0.016, followed by an increase in median EPC/mL from 21.3 (4.7-42.5) to 94.7 (28.2-201.3), p=0.016, prior to clinical relapse. In metastatic patients with progressive disease, median HPC/mL increased from 1696 (10-16470) to 5124 (374-77605), p=0.0009, and median EPC/mL increased from 26 (0-560) to 71 (0-615) prior to progression, p=0.10. In patients with responding disease, median HPC/mL decreased from 6147 (912-85070) to 633 (47-18065), p=0.05, and EPC/mL decreased from 46 (0-197) to 23 (0-105), p=0.41, at response. There were no significant changes in these cells over time in patients with stable disease. Circulating bone marrow-derived HPCs and EPCs predict relapse and disease progression in BC patients.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
11.2
作者：
Dome, Balazs;Timar, Jozsef;Tovari, Jozsef
通讯作者：
Tovari, Jozsef
影响因子：
5.7
作者：
Fujita, Kazutoshi;Nakayama, Masashi;Nonomura, Norio
通讯作者：
Nonomura, Norio
影响因子：
10.3
作者：
Brewster, Abenaa M.;Hortobagyi, Gabriel N.;Esteva, Francisco J.
通讯作者：
Esteva, Francisco J.
影响因子：
9.5
作者：
Friedrich, Erik B.;Werner, Christian;Scheller, Bruno
通讯作者：
Scheller, Bruno